Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies

被引:34
作者
Saeland, E [1 ]
Vidarsson, G [1 ]
Jonsdottir, I [1 ]
机构
[1] Natl Univ Hosp Reykjavik, Dept Immunol, IS-101 Reykjavik, Iceland
关键词
Streptococcus pneumoniae; mice; intranasal challenge; virulence; protection;
D O I
10.1006/mpat.2000.0363
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococci cause infection by colonizing the nasopharynx and invading the mucosal surfaces. Infection models in mice, where the natural route of infection is mimicked, may be useful to study antibody mediated protection against pneumococcal pneumonia and bacteremia. We have established a pneumococcal pneumonia and bacteremia model in mice and investigated the protective capacity of human antibodies. Intranasal challenge with serotypes 1, 3, 6A and 8 caused lung infection and bacteremia which was lethal. Serotype 6B caused low, but detectable, infection and other serotypes tested were not virulent. Passive immunization with a human IgG preparation i.p. protected mice in a dose dependent manner against bacteremia caused by the virulent serotypes (except serotype 3) and partially or completely cleared pneumococci from the lungs of mice infected with serotypes 1, 6A and 8. Adsorption of antibodies with homologous capsular polysaccharides eliminated protection against disease but adsorption with cell wall polysaccharides (CWPS) did not. Furthermore, a good correlation was observed between protection of sera in vivo and opsonic activity in vitro. The results indicate that the model may be useful to analyse the levels, isotypes, specificity and other characteristics of human antibodies which protect against pneumococcal infection and to evaluate the protective potential of pneumococcal vaccine candidates. (C) 2000 Academic Press.
引用
收藏
页码:81 / 91
页数:11
相关论文
共 47 条
[11]   The molecular basis of pneumococcal infection: A hypothesis [J].
Cundell, D ;
Masure, HR ;
Tuomanen, EI .
CLINICAL INFECTIOUS DISEASES, 1995, 21 :S204-S212
[12]   Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens [J].
Dagan, R ;
Melamed, R ;
Zamir, O ;
Leroy, O .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (11) :1053-1059
[13]   EPIDEMIOLOGY OF INVASIVE CHILDHOOD PNEUMOCOCCAL INFECTIONS IN ISRAEL [J].
DAGAN, R ;
ENGLEHARD, D ;
PICCARD, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (23) :3328-3332
[14]   Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines [J].
Daum, RS ;
Hogerman, D ;
Rennels, MB ;
Bewley, K ;
Malinoski, F ;
Rothstein, E ;
Reisinger, K ;
Block, S ;
Keyserling, H ;
Steinhoff, M .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (02) :445-455
[15]   ANTI-POLYSACCHARIDE IMMUNOGLOBULIN ISOTYPE LEVELS AND OPSONIC ACTIVITY OF ANTISERA - RELATIONSHIPS WITH PROTECTION AGAINST STREPTOCOCCUS-PNEUMONIAE INFECTION IN MICE [J].
DEVELASCO, EA ;
DEKKER, BAT ;
VERHEUL, AFM ;
FELDMAN, RG ;
VERHOEF, J ;
SNIPPE, H .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :562-565
[16]   ANTIBODY-RESPONSE TO PNEUMOCOCCAL VACCINATION IN CHILDREN YOUNGER THAN 5-YEARS OF AGE [J].
DOUGLAS, RM ;
PATON, JC ;
DUNCAN, SJ ;
HANSMAN, DJ .
JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (01) :131-137
[17]  
FISCHER RT, 1995, J IMMUNOL, V154, P3373
[18]   INEFFICACY OF PNEUMOCOCCAL VACCINE IN A HIGH-RISK POPULATION [J].
FORRESTER, HL ;
JAHNIGEN, DW ;
LAFORCE, FM .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (03) :425-430
[20]   Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model [J].
Giebink, GS ;
Meier, JD ;
Quartey, MK ;
Liebeler, CL ;
Le, CT .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :119-127